They found that in B16OVA, sialylated O-glycans represent the main source of Siglec-E ligands. In the tumor microenvironment (TME), macrophages, neutrophils, and CD8 but not CD4 T cells expressed Siglec-E, suggesting that these could be the main targets of Siglec-E-mediated immunosuppression.
